TAG:
anatomic pathology services
In-House Versus Off-Site: Different Concerns
By Robert Michel | From the Volume XI No. 10 – July 19, 2004 Issue
CEO SUMMARY: Three methods are available to specialist physician groups to capture anatomic pathology revenues generated by their patient population. Two methods have been around a long time. The pathology condo lab method is a new ploy. Of the three, one is generally accepted and more ea…
Changing Economics Motivate Urologists & GIs
By Robert Michel | From the Volume XI No. 10 – July 19, 2004 Issue
CEO SUMMARY: Over the past 18 months, more specialist groups have created their own anatomic pathology laboratories than were created in the past five years. It’s a gold rush to tap and capture profits generated by the anatomic pathology services provided to their patient populations. T…
National AP Firms Target Gastroenterology Groups
By Robert Michel | From the Volume XI No. 9 – June 28, 2004 Issue
CEO SUMMARY: It’s a trend as yet invisible to the radar screens of most pathology groups. A new crop of specialty AP companies is targeting gastroenterology. In the past 36 months, several have posted phenomenal growth in both specimen volume and revenue. The heightened competition for …
Florida Issues State RFP For Sole Medicaid Lab
By Robert Michel | From the Volume XI No. 5 – April 5, 2004 Issue
CEO SUMMARY: If competitive bidding for Medicare business is something universally viewed as bad by the laboratory industry, then the lab services RFP issued by Florida’s Medicaid program must be considered a serious threat to the status quo. Further, the fact that Medicaid officials in…
IMPATH Has a Buyer: Genzyme Pays $215 Mil
By Robert Michel | From the Volume XI No. 4 – March 15, 2004 Issue
CEO SUMMARY: Two unexpected things happened in IMPATH’s Chapter 11 bankruptcy action. First, it attracted a buyer willing to pay the premium price of $215 million for its assets. Second, the buyer was not another laboratory company. Rather, it is a new entrant into the oncology diagnost…
New Competitors Line Up In Oncology Marketplace
By Robert Michel | From the Volume XI No. 4 – March 15, 2004 Issue
CEO SUMMARY: Local pathology groups are advised to more closely track developments in the national market for oncology testing. Not only is big money targeting cancer testing, but a number of nimble, entrepreneurial start-up companies have begun to compete for specimens. Genzyme’s acqui…
“February 2, 2004 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XI No. 2 – February 2, 2004 Issue
Changes are afoot in the national market for anatomic pathology services. At AmeriPath, Inc., the search is on for a new CEO. Current Chairman and CEO, James C. New retired, effective February 1. The company has commenced the search for a new CEO. New had been with AmeriPath since it…
Anatomic Path Trends Portend Deep Changes
By Robert Michel | From the Volume XI No. 1 – January 12, 2004 Issue
CEO SUMMARY: Our biannual review of trends shaping the anatomic pathology profession reveals that a wide range of influences are active. The nation’s healthcare system is undergoing fundamental changes in how it views the quality of health services and how it will favor top-performing p…
2003’s Big Lab Stories Reflect Health Trends
By Robert Michel | From the Volume X No. 17 – December 22, 2003 Issue
CEO SUMMARY: At a minimum, 2003 proved to be a year of relative stability for the laboratory industry, as demonstrated by THE DARK REPORT’S “Ten Biggest Lab Stories of 2003.” The year was free of industry-wide crises and scan- dals. That allowed most laboratory administrators and pa…
Market Demand for Pathologists Shifts Toward Specialization
By Robert Michel | From the Volume X No. 15 – November 10, 2003 Issue
CEO SUMMARY: Unlike the slack employment market for pathologists seen during the 1990s, there is strong demand for pathologists in this decade. Private pathology group practices now face competition for the best pathology talent. That’s because public lab companies are regularly in the …
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized